2017 Global Market Top10 Pharmaceuticals | GSK slipped out of the list | Merck's fleeting disadvantage

Pharmaceutical Network December 1 hearing the United States GEN was founded in 1981, is the world's leading authoritative biotechnology media, November 27, GEN website released by market value of the 2017 annual global TOP10 pharmaceutical companies.

Below is the list of top 10 pharmaceutical companies this year, ranked by market capitalization as of November 9, 2017. The data come from the company's websites, stock exchange websites and other open channels. The data of non-U.S. companies are converted into U.S. dollars according to the exchange rate of the day.

Global top 10 pharmaceutical companies (unit: billion dollars)

Overall, most of the traditional pharmaceutical companies this year are outperforming biotech companies, and when biotech companies fall into the disappointment or failure of clinical trials at Q3, pharmaceutical companies seem to be getting even better this year.

As of November 9, 2017, the ARCA Pharmaceuticals Index on the New York Stock Exchange increased 7.8% from the same period last year to $ 536.86 while the TOP 10 pharmaceutical company in the GEN list has a combined market capitalization of $ 1.722 trillion this year Last year's Top10 list of companies 1.568 trillion US dollars increased by 9.8% over 2015 TOP 10 of 1.626 trillion US dollars increased by 5.9%.

• Sales of blockbusters over $ 1 billion in annual sales continue to grow;

• FDA's new director, Scott Gottlieb, led the process to simplify the listing of new drugs and more new drugs were approved.

• Corporate tax cuts introduced by the Trump administration;

• Trump's policy of lowering drug prices did not materialize on schedule;

Pharmaceuticals enterprise Turn from bulk mergers to smaller, reinforced acquisitions.

Compared with last year, only one company GSK (No. 6 in 2016) slid out of the list this year, with a market capitalization of 66.38 billion pounds (about 87.29 billion U.S. dollars), down 16% from 103.82 billion U.S. dollars last year, replacing GSK TOP 10 is Eli Lilly and Company, which ranked 11th last year with a market capitalization of 86.63 billion US dollars.

Even more encouraging is that, with the exception of Merck, the market capitalization of each of TOP 10's pharmaceutical companies has increased from last year's level, and the rankings in Albers and Bayer have all risen. Merck has slipped from 1 to 6 in 2016 , Was ranked No. 7 in the previous year's Albert Polo more than.

On October 27, 2017, Merck claimed Q3 revenue fell 2% from Q3 2010 to US $ 10.325 billion from Q10 of US $ 10.536 billion. Merdhams provided several reasons for the decline in revenue. For example, Mercuria suffered a cyber attack this year resulting in 9 Jiajia reached a standstill, resulting in a loss of sales of 135 million U.S. dollars. In fact, the U.S. CDC reserves an order of 240 million U.S. dollars worth of Jiaoda repair.

There are other reasons drug Sales fell 3% to $ 9.2bn mainly due to the patented cliffs of the downshift steroids (Zetia, ezetimibe) and Vytorin (ezetimibe / simvastatin) In addition to the loss of market monopoly in the United States at the end of last year and early April this year, Cubist's antibiotic antibiotic Cubicin (Daptomycin for Injection) acquired at the end of 2014 is also facing competition from generic drugs. Remicade, Infliximab) is also facing biosimilars competition in Europe.